Literature DB >> 9614214

Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives.

M Baba1, M Okamoto, M Kawamura, M Makino, T Higashida, T Takashi, Y Kimura, T Ikeuchi, T Tetsuka, T Okamoto.   

Abstract

We have recently identified 8-difluoromethoxy-1-ethyl-6-fluoro-1, 4-dihydro-7-[4-(2-methoxyphenyl)-1-piperazinyl]-4-oxoquinoline-3-carb oxylic acid (K-12) as a potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1) transcription. In the search for more effective derivatives and their mode of action, we have found 7-(3,4-dehydro-4-phenyl-1-piperidinyl)-1, 4-dihydro-6-fluoro-1-methyl-8-trifluoromethyl-4-oxoquinoline-3- carboxylic acid (K-37) and 8-difluoromethoxy-1,4-dihydro-6-fluoro-7-(3, 4-dehydro-4-phenyl-1-piperidinyl)1-[4,(1,2, 4-triazol-1-yl)methylphenyl]-4-oxoquinoline-3-carboxylic acid (K-38) to be more potent inhibitors of HIV-1 replication than K-12. The EC50 values of K-37 and K-38 for HIV-1IIIB were 27 and 3.8 nM in peripheral blood mononuclear cells, respectively. These values were approximately 3- and 24-fold lower than the EC50 of K-12. K-38 was also a more potent inhibitor of HIV-1 replication in chronically infected cells, such as tumor necrosis factor alpha-stimulated OM-10. 1 cells. K-37 and K-38 proved to be more cytotoxic than K-12 for a variety of cell lines as well as peripheral blood mononuclear cells. These compounds were more inhibitory of Tat-induced HIV-1 long terminal repeat-driven gene expression than K-12, which suggests that their mechanism of action is attributable in part to the inhibition of Tat function. Interestingly, K-37 and K-38 could suppress the production of tumor necrosis factor alpha and interleukin 6 in phytohemagglutinin-stimulated peripheral blood mononuclear cells and the expression of intercellular adhesion molecule 1 in tumor necrosis factor alpha-stimulated human umbilical vein endothelial cells at their nontoxic concentrations. In contrast, another K-12 derivative, 1, 4-dihydro-8-dimethylaminomethyl-6-fluoro-7-[4-(2-methoxyphenyl)-1-pip eradinyl]-1-methyl-4-oxoquinoline-3-carboxylic acid (K-42), had anti-HIV-1 activity and cytotoxicity profiles similar to those of K-12, but K-42 scarcely inhibited the cytokine production and intercellular adhesion molecule 1 expression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9614214

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  20 in total

1.  Identification of BPR3P0128 as an inhibitor of cap-snatching activities of influenza virus.

Authors:  John T-A Hsu; Jiann-Yih Yeh; Ta-Jen Lin; Mei-Ling Li; Ming-Sian Wu; Chung-Fan Hsieh; Yao Chieh Chou; Wen-Fang Tang; Kean Seng Lau; Hui-Chen Hung; Ming-Yu Fang; Shengkai Ko; Hsing-Pang Hsieh; Jim-Tong Horng
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors.

Authors:  Kylene Kehn-Hall; Irene Guendel; Lawrence Carpio; Leandros Skaltsounis; Laurent Meijer; Lena Al-Harthi; Joseph P Steiner; Avindra Nath; Olaf Kutsch; Fatah Kashanchi
Journal:  Virology       Date:  2011-04-22       Impact factor: 3.616

3.  Inhibition of human immunodeficiency virus type 1 tat-trans-activation-responsive region interaction by an antiviral quinolone derivative.

Authors:  Sara Richter; Cristina Parolin; Barbara Gatto; Claudia Del Vecchio; Egidio Brocca-Cofano; Arnaldo Fravolini; Giorgio Palù; Manlio Palumbo
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

4.  Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication.

Authors:  Irene Guendel; Sergey Iordanskiy; Rachel Van Duyne; Kylene Kehn-Hall; Mohammed Saifuddin; Ravi Das; Elizabeth Jaworski; Gavin C Sampey; Svetlana Senina; Leonard Shultz; Aarthi Narayanan; Hao Chen; Benjamin Lepene; Chen Zeng; Fatah Kashanchi
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

5.  A reporter based single step assay for evaluation of inhibitors targeting HIV-1 Rev-RRE interaction.

Authors:  Sumeer Raina; Ajit G Chande; Masanori Baba; Robin Mukhopadhyaya
Journal:  Virusdisease       Date:  2013-09-27

6.  Inhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces species.

Authors:  M Baba; M Okamoto; H Takeuchi
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

7.  Novel in vivo model for the study of human immunodeficiency virus type 1 transcription inhibitors: evaluation of new 6-desfluoroquinolone derivatives.

Authors:  Miguel Stevens; Michela Pollicita; Christophe Pannecouque; Erik Verbeken; Oriana Tabarrini; Violetta Cecchetti; Stefano Aquaro; Carlo Federico Perno; Arnaldo Fravolini; Erik De Clercq; Dominique Schols; Jan Balzarini
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

8.  Identification of novel inhibitors of human immunodeficiency virus type 1 replication by in silico screening targeting cyclin T1/Tat interaction.

Authors:  Takayuki Hamasaki; Mika Okamoto; Masanori Baba
Journal:  Antimicrob Agents Chemother       Date:  2012-12-28       Impact factor: 5.191

9.  Ethyl 4-(3-hydroxy-phen-yl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexa-hydro-quinoline-3-carboxyl-ate.

Authors:  P Mookiah; K Rajesh; T Narasimhamurthy; V Vijayakumar; N Srinivasan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-10-07

10.  The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.

Authors:  Joeri Auwerx; Miguel Stevens; An R Van Rompay; Louise E Bird; Jingshan Ren; Erik De Clercq; Bo Oberg; David K Stammers; Anna Karlsson; Jan Balzarini
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.